Technological University Dublin

ARROW@TU Dublin
Articles

School of Food Science and Environmental
Health

2014

New Inhibitors of the FVB2 Subunit from Mammalian Kv1
Potassium Channels
Barry Ryan
Technological University Dublin, barry.ryan@tudublin.ie

Gary Henehan
Technological University Dublin, gary.henehan@tudublin.ie

Alka Kumari

See next page for additional authors

Follow this and additional works at: https://arrow.tudublin.ie/schfsehart
Part of the Life Sciences Commons

Recommended Citation
Alka, K., Dolly, O.J., Ryan, B.J., and Henehan, G.T. (2014). New inhibitors of the KVB2 subunit from the
mammalian potassium channels. The International Journal of Biochemistry and Cell Biology, 55, 35-39.
http://dx.doi.org/10.1016/j.biocel.2014.07.013

This Article is brought to you for free and open access by
the School of Food Science and Environmental Health at
ARROW@TU Dublin. It has been accepted for inclusion in
Articles by an authorized administrator of ARROW@TU
Dublin. For more information, please contact
arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Authors
Barry Ryan, Gary Henehan, Alka Kumari, and Oliver Dolly

This article is available at ARROW@TU Dublin: https://arrow.tudublin.ie/schfsehart/173

G Model

ARTICLE IN PRESS

BC 4391 1–5

The International Journal of Biochemistry & Cell Biology xxx (2014) xxx–xxx

Contents lists available at ScienceDirect

The International Journal of Biochemistry
& Cell Biology
journal homepage: www.elsevier.com/locate/biocel

Short communication

1

New inhibitors of the Kv␤2 subunit from mammalian Kv1 potassium
channels

2

3

4
5
6

Q1

Kumari Alka a , J. Oliver Dolly b , Barry J. Ryan a , Gary T.M. Henehan a,∗
a
b

School of Food Science and Environmental Health, Dublin Institute of Technology (DIT), Cathal Brugha Street, Dublin 1, Ireland
International Centre for Neurotherapeutics, Dublin City University, Dublin 9, Ireland

7

8
23

a r t i c l e

i n f o

a b s t r a c t

9
10
11
12
13
14

Article history:
Received 27 February 2014
Received in revised form 1 July 2014
Accepted 16 July 2014
Available online xxx

15

Keywords:
ˇ Subunit
K+ channels
18
Inhibition
19
DOPAC
20
Cortisone
21
22 Q2 Aldo-keto reductase
16
17

24

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

The role of the redox state of Kv␤ subunits in the modulation of Kv1 potassium channels has been well
documented over the past few years. It has been suggested that a molecule that binds to or inhibits the
aldo-keto reductase activity of Kv␤ might affect the modulation of channel properties. Previous studies
of possible modulators of channel activity have shown that cortisone and some related compounds are
able to physically dissociate the channel components by binding to a site at the interface between ␣ and
␤ subunits. Herein, we describe some new inhibitors of rat brain Kv␤2, identiﬁed using an assay based
on multiple substrate turnover. This approach allows one to focus on molecules that speciﬁcally block
NADPH oxidation. These studies showed that, at 0.5 mM, 3,4-dihydroxphenylacetic acid (DOPAC) was
an inhibitor of Kv␤2 turnover yielding a ∼40–50% reduction in the aldehyde reductase activity of this
subunit. Other signiﬁcant inhibitors include the bioﬂavinoid, rutin and the polyphenol resveratrol; some
of the known cardioprotective effects of these molecules may be attributable to Kv1 channel modulation.
Cortisone or catechol caused moderate inhibition of Kv␤2 turnover, and the aldo-keto reductases inhibitor
valproate had an even smaller effect.
Despite the importance of the Kv1 channels in a number of disease states, there have been few Kv␤2
inhibitors reported. While the ones identiﬁed in this study are only effective at high concentrations, they
could serve as tools to decipher the role of Kv␤2 in vivo and, eventually, inform the development of novel
therapeutics.
© 2014 Published by Elsevier Ltd.

1. Introduction
The Shaker voltage-gated K+ channels (Kv1 superfamily) control the efﬂux of K+ through cell membranes and, thereby, dampen
membrane excitability. An auxillary ␤-subunit (Kv␤), associated
with the cytoplasmic face of Kv proteins (Dolly et al., 1994; Parcej
et al., 1992; Scott et al., 1994) has sequence homology with aldoketo reductase (AKR) enzymes (Gulbis et al., 1999; Long et al., 2005).
The catalytic C-terminal of Kv␤2 has a tightly, but non-covalently,
bound nicotinamide (NADPH) cofactor. Most signiﬁcantly, Kv␤ is
known to modulate the channel’s activity in a manner that depends
on the redox state of the bound cofactor. This mechanism is thought
to proceed via redox dependent conformational changes (Weng et
al., 2006; Pan et al., 2008b, 2011). The Kv␤ subunit is catalytically
active as an aldo-keto reductases being able to reversibly oxidise
a range of alcohols to their corresponding aldehydes (Alka et al.,
2010; Tipparaju et al., 2008).

∗ Corresponding author. Tel.: +353 1 402 4408; fax: +353 1 402 4495.
E-mail address: gary.henehan@dit.ie (G.T.M. Henehan).

Allelic deletion of Kv␤ is directly linked to severe epilepsy
including infantile spasm (Heilstedt et al., 2001) while loss-offunction mutations in pore forming ␣-subunits are associated with
convulsive disorders (Adelman et al., 1995; Guan et al., 2006;
Imbrici et al., 2006, 2007). It has been suggested that inhibitors
of the action of Kv␤ might prove useful as therapeutics (Pan et al.,
2008a, 2012). Despite this, there have been few reports of compounds that might inhibit Kv␤.
In 2008, Pan et al., screened a number of potential Kv␤ inhibitors
and showed that cortisone can bind to Kv␤ proteins at two different sites: one close to the enzyme bound NADPH and another at
the interface between Kv␤ and Kv1 ␣ subunits (Pan et al., 2008a).
They further showed that cortisone promotes dissociation of Kv␤
from Kv1 subunits, a ﬁnding that focused attention on inhibitors
that might target the interface between subunits in Kv1 channels. Subsequently, these authors tested 25 cortisone analogues
for their ability to potentiate Kv1 channels by binding to Kv␤ and
promoting its dissociation (Pan et al., 2012). Their work identiﬁed ﬂuticasone as a potential lead for designing more efﬁcient
small molecules that might inﬂuence channel function by dissociating the Kv1–Kv␤ assembly. Nevertheless, there is little or no

http://dx.doi.org/10.1016/j.biocel.2014.07.013
1357-2725/© 2014 Published by Elsevier Ltd.
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information on molecules, other than substrates and corticosteroids, that can bind to the active site of the Kv␤ subunit. Predicting
inhibitors for this protein is difﬁcult since even studies on substrate
speciﬁcity have proven somewhat confusing (Alka et al., 2010;
Tipparaju et al., 2008).
Herein, the interactions of a variety of small molecules with
the active site of Kv␤2 were probed. The tightly bound NADPH on
Kv␤2 may dissociate and allow measurement of multiple turnovers
(Weng et al., 2006). We exploit this activity to screen for Kv␤2
inhibitors that have a direct inﬂuence on substrate turnover. This
approach utilised a simple HPLC-based assay to monitor the Kv␤2catalysed reduction of 4-nitrobenzaldehyde (see Alka et al., 2010).
This assay was used for screening of small molecule inhibitors that
might bind to Kv␤2 and inhibit the redox reaction. In this way,
inhibitors were sought for NADPH oxidation rather than modulators of channel function, since this oxidation step is known to
inﬂuence channel activity.
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The rat brain Kv␤2 protein was overexpressed in, and puriﬁed from, Escherichia coli BL21 (DE3, plysS) cells transformed
with the pET15b-Kv␤2 construct containing an N-terminal His-tag,
described in Alka et al., 2010. The puriﬁed protein was dialysed
against 2 L of prechilled 0.2 M potassium phosphate, pH 7.5 for 36 h
with three changes.
2.2. HPLC assay for measuring the inhibition of Kvˇ2-mediated
4-nitrobenzaldehyde reduction
Two different HPLC separation methods (Isocratic and Gradient)
were used to carry out the inhibition studies for the Kv␤2 mediatedreduction of 4-nitrobenzaldehyde. The one chosen depended on
the effective separation of the inhibitor from components of
the reaction mixture. All inhibition studies were carried out in
duplicate in 0.2 M potassium phosphate buffer, pH 7.5 containing 0.2 mM NADPH at 37 ◦ C in the presence of ∼0.5 mg of Kv␤2,
an appropriate concentration of each test inhibitor and 500 M
of 4-nitrobenzaldehyde as substrate (ﬁnal volume of 0.25 ml). A
100 mM stock solution of all inhibitors was prepared in DMSO.
The concentration of DMSO in the assay mixture was less than
or equal to 1% (v/v). DMSO at this concentration was found to
have no effect on the 4-nitrobenzaldehyde reductase activity of
Kv␤2. The inhibitor was incubated with the enzyme for 20 min
before the addition of substrate, which was added last, and the
reaction further incubated for 30 min at 22 ◦ C before quenching by
adding an equal volume of the HPLC mobile phase consisting of
methanol/triﬂuroacetic acid/water (60: 0.1: 39.9, v/v/v). Aliquots,
(10 l), of the resultant mixture were analysed on a Nucleosil C18
(3.9 × 150 mm) HPLC column, using Waters 2695 family of Separations modules (Waters Corporation, Milford, USA) with monitoring
by a Waters 2998 photodiode array detector at 274 nm. The column temperature was 37 ◦ C. Controls without enzyme were used
to monitor any background reaction between the inhibitor and the
substrate 4-nitrobenzaldehyde.
2.2.1. Gradient HPLC assay
Solvent A was a mixture of methanol/triﬂuroacetic acid/water
(60: 0.1: 39.9) while solvent B comprised methanol/triﬂuroacetic
acid/water (20: 0.1: 79.9). The following linear gradient was
used for the separation: 20–100% B (15 min), 100% B (5 min) and
100–20% B (0.1 min) at 0.9 mL/min. The run time was 20 min.
Standard curves constructed using each method separately for

4-nitrobenzaldehyde and 4-nitrobenzyl alcohol were used to determine concentrations of product in each of the reaction mixtures.
2.2.2. Isocratic elution method
Solvent A (100%) was used as mobile phase with a total acquisition time of 10 min for the isocratic elusion method while the
procedure for determination of product concentration was the
same as described above (Section 2.2.1)
2.3. Fluorescence measurement of inhibitor binding to Kvˇ2
Fluorescence scans of Kv␤2 with bound NADPH were recorded
on a Perkin Elmer ﬂuorescence spectrometer LS50B at 22 ◦ C. Binding studies were carried out in a quartz cuvette containing ∼2.0 M
Kv␤2-bound NADPH in 0.2 M potassium phosphate buffer, pH 7.5 at
22 ◦ C. The reaction volume was 2 ml. All inhibitor solutions (Stock
concentration 100 mM) were prepared in DMSO and then diluted
into 0.2 M potassium phosphate buffer, pH 7.5 to the required concentration, keeping the content of DMSO in the reaction mixture
equal to or below 1% (v/v). DMSO at this concentration had no effect
on enzyme-bound NADPH. The ﬂuorimeter excitation wavelength
used was 360 nm with a slit size of 15 nm and emission spectra were
acquired from 300 to 600 nm. After a spectrum was recorded, 10 l
of inhibitor stock solution was added into the Kv␤2 solution and
mixed. A spectrum was recorded immediately after mixing (1 min)
and at different time points afterwards.
3. Results and discussion
3.1. Inhibitors of the ˇ-subunit from voltage-sensitive potassium
channels
Table 1 shows the compounds tested for their ability to inhibit
Kv␤2-mediated reduction of 4-nitrobenzaldehyde. Although it has
previously proven somewhat difﬁcult to ﬁnd molecules that bind
to Kv␤2 as inhibitors in this study several molecules were found
that were capable of binding to, and inhibiting, Kv␤2.
3.1.1. DOPAC and catechol
3,4-Dihydroxphenylacetic acid (DOPAC), the acid metabolite
of dopamine inhibited Kv␤2 in a concentration-dependent and
saturable manner (Fig. 1A). Under the conditions used in this
study, DOPAC was found to be the most effective inhibitor of
Kv␤2 of all the molecules tested, showing ∼40% reduction in 4nitrobenzaldehyde reductase activity (Table 1). The inhibition was
found to be concentration dependent (Fig. 1A). Interestingly, catechol, which has a structure like DOPAC but without the acetate
group, was found to be far less effective (16% Inhibition, see Table 1).
While the observed DOPAC inhibition is only 40%, it is of interest
to ﬁnd that this neurotransmitter metabolite is capable of binding
to Kv␤2, particularly considering ﬁndings regarding the role of Kv1
channels in regulating dopamine release (see Martel et al., 2011).
3.1.2. Cortisone
Structural studies have shown cortisone to bind at two different sites on Kv␤2: one close to the NADPH cofactor binding site and
another at an interface site between the ␣ and ␤ subunits (Pan et
al., 2008a). It was, therefore, expected that cortisone might inhibit
Kv␤2. Indeed, this study shows that cortisone does inhibit Kv␤2
activity but only by ∼18% (Table 1). This inhibition was further
shown to be concentration dependent (Fig. 1B). Such a relatively
modest inhibition by cortisone supports the idea that its main effect
on channel activity is likely via dissociation of Kv␤2 from Kv1 (Pan
et al., 2008a).
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Table 1
Inhibitors of Kv␤2-mediated aldehyde reduction. All data are expressed as mean of triplicate measurements.
Inhibitor (0.5 mM)

Description of inhibitor

Percentage inhibitiona

Sodium valproate
4-Nitrobenzoic acid
4-Chlorobenzaldehyde
4-Fluorobenzaldehyde
Anisaldehyde
Tolualdehyde
Chloral hydrate
4-nitoacetophenone
Rutin hydrate
Resveratrol
Cortisone
Pyrazole
Cyproheptadine
Amitriptyline hydrochloride
d-Sorbitol
Chlorpromazine hydrochloride
DOPAC
Catechol
5-Hydroxyindole-3-acetic acid

Classical AKR inhibitor/anticonvulsant
Kv␤2 catalysed reaction product
Substrate analogue
Substrate analogue
Substrate analogue
Substrate analogue
Sedative and hypnotic drug
Aromatic ketone
Plant ﬂavanoid
Chemopreventive/cardioprotective/antiaging
Steroid hormone
Analgesic/anti-inﬂammatory
Antidepressant
Antidepressant
Sugar alcohol
Antipsychotic drug
Dopamine metabolite
Structural variant of DOPAC
Serotonin metabolite

10 ± 0.8
0
6 ± 0.5
3 ± 0.8
0
0
0
6 ± 0.6
38 ± 2
38 ± 1
18 ± 2
0
0
0
0
0
40 ± 4
16 ± 0.7
0

a
The amount of 4-nitrobenzyl alcohol produced as a result of Kv␤2-mediated multiple turnover of 4-nitrobenzaldehyde with no inhibitor was taken as 100%. Activities in the presence of inhibitor were expressed as a percentage of control 4-nitrobenzaldehyde reductase activity. Enzyme activity was measured as described in
Section 2.

176
177
178
179
180

3.1.3. Sodium valproate
This anti-convulsant drug, which is a classical inhibitor of many
aldo-keto reductases, (Hinshelwood et al., 2002; Todaka et al.,
2000) proved to be a rather poor inhibitor showing a 20% reduction
in 4-nitrobenzaldehyde activity of Kv␤2 at 0.5 mM (Table 1).

3.1.4. Rutin
Rutin, a naturally-occurring plant ﬂavanoid known to inhibit
aldose reductase from rat brain (Wermuth et al., 1982), reduced
Kv␤2 aldehyde reductase activity by ∼38% at 0.5 mM (Table 1).
A concentration-dependent increase in inhibition was observed

Fig. 1. Concentration dependent inhibition of Kv␤2 by various inhibitors. The data show the percentage inhibition as a function of increasing concentration of (A) DOPAC
(0–700 M), (B) cortisone (0–1000 M), (C) rutin (0–2000 M), (D) Resveratrol (0–2000 m). The assay mixture contained ∼0.5 mg Kv␤2 in 0.2 M potassium phosphate
buffer (pH 7.5), along with 500 M 4-nitrobenzaldehyde as substrate, 200 M NADPH and various concentrations of inhibitor in a ﬁnal reaction volume of 250 l at 37 ◦ C.
After the addition of inhibitor to Kv␤2 containing NADPH, the reaction was initiated by the addition of the substrate (4-nitrobenzaldehyde) and incubated for 30 min. The
amounts of the reduced product (4-nitrobenzylalcohol) formed were analysed by HPLC, as described in Section 2. Percentage inhibition of the 4-nitrobenzaldehyde reductase
activity of Kv␤2 at different starting concentrations of inhibitor was plotted against inhibitor concentration. Data are expressed as the mean of triplicate measurements. The
points were ﬁtted to a rectangular hyperbolic curve using prism 6.0.
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(Fig. 1C), giving a maximal level of inhibition only slightly less than
that observed with DOPAC.
3.1.5. Resveratrol
Kv␤2 inhibition by resveratrol was examined since it has been
shown to have chemopreventive, cardioprotective, and anti-ageing
properties which may be mediated by inhibition of a reductase
(Buryanovskyy et al., 2004). Resveratrol (0.5 mM) inhibited Kv␤2
activity in a concentration-dependent manner but to a maximal
level of ∼40% (Fig. 1D). It is interesting to speculate that some
of the cardioprotective effects attributed to resveratrol might be
mediated by Kv␤2 inhibition.
3.1.6. Other compounds tested
4-Nitrobezoic acid showed no inhibition showing that Kv␤2
was not liable to product inhibition under these conditions.
anisaldehyde, cyproheptadine, chloral hydrate, d-sorbitol, chlorpromazine and 5-hydroxyindole-3-acetic acid all failed to inhibit
Kv␤2. The antidepressants amitriptyline and cyproheptadine (a
known potassium channel blocker, Wooltorton and Mathie, 1993)
were, likewise, devoid of effect on Kv␤2. The antipsychotic drug,
chlorpromazine and the serotonin metabolite 5-hydroxyindole-3acetic acid showed no measurable inhibition of Kv␤2.

226

3.1.7. Summary of inhibition ﬁndings
As with the substrate speciﬁcity studies mentioned above
it is difﬁcult to deduce common features that will deﬁne a
Kv␤2 inhibitor. A variety of aldehydes might be expected to
be inhibitors or substrates. However, the fully hydrated aldehyde, chloral hydrate, did not inhibit neither did a several
aromatic aldehydes although 6% inhibition was observed with 4chlorobenzaldehyde. Sodium valproate did show some inhibition
(10%) indicating that a carboxylate might be necessary for inhibition, however, 4-nitrobenzoate did not inhibit. On the other
hand, 5-nitroacetophenone did inhibit albeit by only 6%. Catechol
inhibited Kv␤2 by 16% but DOPAC which consists of catechol bearing an acetate group inhibited by 40%. This again suggests that a
carboxylate is desirable for inhibition. Large multi ring structures
such as amitriptyline, chlorpromazine and cyproheptadine were
not inhibitory presumably due to their bulk. On the other hand the
multi ring structure of rutin was inhibitory. These ﬁndings probably reﬂect an active site with a high degree of speciﬁcity. The most
signiﬁcant inhibition was observed with DOPAC, rutin hydrate and
resveratrol.
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3.2. Inhibitor binding studies

207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225

It was possible that some of the compounds tested might be
binding to sites other than the active site of Kv␤2. In 2008, Pan et
229
al., identiﬁed an interface site that promotes dissociation of Kv␤2
230
from Kv1. It is not known if this site will bind cortisone in the
231
absence of Kv1 ␣ subunits. Moreover, because some of the com232
pounds tested might be substrates for Kv␤2, the binding of the
233
inhibitors to the Kv␤2-active site was examined by monitoring the
234
quenching of the cofactor ﬂorescence peak at 450 nm. This effect on
235
ﬂuorescence intensity is different from that induced by a substrate,
236
which oxidises the Kv␤2-bound NADPH and, thereby, eliminates
237
the ﬂuorescence peak (Alka et al., 2010; Pan et al., 2008a). Binding
238
studies carried out for cortisone, DOPAC, catechol, rutin and resver239
atrol yielded reductions in the ﬂuorescence intensity at 450 nm of
240
16 ± 0.7%, 7 ± 0.3%, 12 ± 0.8% and 16 ± 1.1%, respectively immedi241
ately after their addition; the decreased signals remained almost
242
constant for 20 min. The data for DOPAC and cortisone are illus243
trated in Fig. 2A and B; ﬁndings with the latter agree well with
244
Q3 a report from Pan et al., 2009. In the same year, Tipparaju et al.,
245
reported cortisone as a poor substrate for Kv␤2; this was not
246
228

Fig. 2. Fluorescence quenching studies of Kv␤2. Fluorescence spectra of Kv␤2
before (blue) and 20 min after mixing (shown in red and green) with 0.5 mM cortisone/DOPAC (A and B respectively) showing 16 and 7% reduction in ﬂuorescence at
450 nm. The change in ﬂuorescence of the Kv␤2 bound cofactor occurred immediately after the addition of the inhibitor and remained stable for 20 min. All assays
were carried out as detailed in Section 2. The addition of 10 l DMSO showed no signiﬁcant reduction in the ﬂuorescence spectrum of Kv␤2 under the conditions used
(data not shown). (For interpretation of the references to color in this ﬁgure legend,
Q6
the reader is referred to the web version of the article.)

observed in the present study. Indeed, none of the inhibitors tested
identiﬁed in this study were Kv␤2 substrates.
4. Conclusion
Previous studies of modulators of Kv1 channel activity have
focused on cortisone and its analogues (Pan et al., 2008a, 2012).
The present study advances the search for inhibitors of Kv␤2 by
identifying several new compounds that bind to this subunit that
speciﬁcally inhibit substrate turnover and, therefore, are likely to
have a quite different mechanism of action from cortisone which
appears to exert its inﬂuence in large part by dissociating Kv␤ from
Kv1.
It is surprising that, given the sequence homology between Kv␤
proteins and AKR enzymes, there is very little inhibition of this
subunit activity by classical AKR inhibitors; in fact, there are few
compounds that appear to bind tightly to this protein and this
includes substrates (see Pan et al., 2012; Alka et al., 2010).
Interestingly, DOPAC (the acid degradation product of
dopamine) was found to be an effective inhibitor of Kv␤2.
Dopamine is released by several areas of the brain and these ﬁndings make DOPAC a possible in vivo effector of brain Kv␤2. However,
the concentration at which inhibition was observed is quite high.
DOPAC is only the second physiological compound shown to inhibit
Kv␤2 activity. Physiologically, Dopamine undergoes catabolism
by monoamine oxidase to 3,4-dihydroxyphenylacetaldehyde
(DOPAL), which is further oxidised to 3,4-dihydroxyphenylacetic
acid (DOPAC) by aldehyde dehydrogenase. It is unlikely that
DOPAC levels in vivo will approach those used in this study (Jing et
al., 2007) unless in localised microenvironments.
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Scheme 1. Scheme showing partial inhibition of an enzyme catalysed reaction
where E, S and I represent enzyme, substrate and inhibitor, respectively. Terms Kcat
and K cat represent the catalytic rate constants for the breakdown of the ES and ESI
complexes, respectively (McDonald and Tipton, 2002).
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Cortisone was found to inﬂuence aldehyde turnover as predicted, but rutin and resveratrol were at least as effective in this
regard. Resveratrol, a polyphenolic compound found in red wine,
is well known for its cardioprotective (Markus and Morris, 2008;
Nicholson et al., 2008) and anti-cancer effects (Chen et al., 2004;
He et al., 2011). Its observed inhibition of the catalytic activity of
Kv␤2 may relate to some of the therapeutic properties exhibited
by resveratrol.
It is acknowledged that the concentrations used to achieve Kv␤2
inhibition are high and the degree of inhibition does not exceed 40%
in any cases. The lack of inhibition studies in the literature for this
subunit may be due to difﬁculties in identifying any molecules that
can bind to Kv␤2. It is important to note that cortisone does not
greatly inhibit aldehyde turnover by this subunit but it has nonetheless been shown to have a signiﬁcant effect on channel activity (see
Pan et al., 2008a).
It is important to note that while the inhibitors examined here
showed concentration dependence they did not give rise to complete inhibition in any case. This precluded the measurement of IC50
values. Moreover, a plot of enzyme activity versus inhibitor concentration was saturable. Inhibition of this kind is normally regarded
as partial and can be explained by assuming that inhibitor binding
does not fully exclude substrate turnover (Scheme 1).
An alternative explanation, where inhibition is caused by binding at a site other than the active site in a manner that constrains
substrate binding, is also possible but was discounted on the basis of
the ﬂuorescent quenching studies. Moreover, direct binding of cortisone to the active site was observed previously (Pan et al., 2008a).
Of course, such an explanation might be considered where such
binding gave rise to perturbation of the active site in a way that
caused ﬂuorescence quenching. Further kinetic studies are needed
to distinguish these possibilities.
The compounds described here may help to provide a starting point to stimulate further exploration of Kv␤2 inhibitors. In
summary, a number of molecules were identiﬁed that bind to and
inhibit Kv␤2-mediated p-nitrobenzaldehyde reduction, including
the steroid cortisone.
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